The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
One thousand times more soluble than L-cystine at neutral pH
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The appointment is effective from May 01, 2023 for five years
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
